We are live on ! Find out more
VRAX icon

Virax Biolabs

4 hedge funds and large institutions have $183K invested in Virax Biolabs in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.51% more ownership

Funds ownership: 0% → 0.51% (+0.51%)

Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

VRAX Hedge Fund Activity: Q3 2022 in Review

4 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2022, worth a combined $183K.

Buyers outnumbered sellers: 4 funds opened new VRAX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $241K.

  • 4 institutional investors held Virax Biolabs (VRAX) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $183K of Virax Biolabs stock for Q3 2022.
  • 4 funds opened new Virax Biolabs positions in Q3 2022 and 0 closed out, a net change of +4 holders.
  • The largest Virax Biolabs buyer in Q3 2022 was Schonfeld Strategic Advisors, an estimated $241K added.

Based on aggregated 13F filings for Q3 2022.